JW Pharmaceutical
Daily close in US$ at the latest USD/KRW close. Source: KRX via FinanceDataReader.
JW Pharmaceutical makes prescription medicines and other pharmaceutical products supplied to hospitals, clinics, and patients in Korea.
The company is listed on KOSPI, Korea's main stock exchange, and has operated as a mid-sized pharmaceutical business for decades. It consolidates five unlisted subsidiaries within its reported financials, reflecting a group structure built around its core drug business.
Summary is AI-generated and may contain errors · figures from DART filings
JW Pharmaceutical classifies itself as a mid-sized enterprise under Korean corporate law, placing it in a category between a small business and a large conglomerate.
JW Pharmaceutical in five facts
What does JW Pharmaceutical do?
JW Pharmaceutical makes prescription medicines and other pharmaceutical products supplied to hospitals, clinics, and patients in Korea.
Where is JW Pharmaceutical listed and in which sector?
JW Pharmaceutical (Korean name: JW중외제약) trades under KRX code 001060 on KOSPI, the main board of the Korea Exchange. It is classified in the Health Care sector, Pharmaceuticals.
How large is JW Pharmaceutical?
Its market capitalisation was US$438.5M on 2026-10-21, which puts it in this site's small-cap group. US$ amounts are converted from won at 1 USD ≈ ₩1,325 (2026-10-21).
What were JW Pharmaceutical's latest annual revenue and operating profit?
For fiscal year 2025, JW Pharmaceutical reported revenue of US$585.2M, operating profit of US$71.3M and net income of US$46.4M, per its annual report on DART (data retrieved from DART on 2026-09-05). Revenue was up 7.8% on the previous year.
Where does this data come from?
Financial statements and filings come from DART, Korea's official corporate-filing system. Share prices, market capitalisation and trading status come from KRX. Company summaries are AI-generated from the filings and may contain errors; financial figures are mapped directly from DART.
Data sources and last updated
- Filings and financial statements
- DART (dart.fss.or.kr), Korea's official corporate-filing system
- Prices, market cap, trading status
- KRX (Korea Exchange), via FinanceDataReader
- Latest annual financials
- Fiscal year 2025, data retrieved from DART on 2026-09-05
- Share price and market cap
- Close of 2026-10-21
- Currency
- US$, converted from won at 1 USD ≈ ₩1,325 (2026-10-21 close)
- Company data updated
- 2026-10-21
- Company summary
- AI-generated from filings; may contain errors. Information only, not investment advice.
- [Amended] DisclosureOct 8
- Decision to acquire shares/equity in another company
JW Pharmaceutical disclosed an acquisition of Solidus Investment Co., Ltd., worth US$22.8M.
M&A · Sep 29 - [Amended] DisclosureSep 18
- Change in shares held by the largest shareholderSep 17
- Report on large shareholdings (5% rule) (standard)Sep 17
- Report on securities held by executives/major shareholdersSep 17
- Operating results (preliminary) (fair disclosure)
JW Pharmaceutical filed provisional (unaudited) separate results for Q2 2026: revenue of US$156M (+16.1% year on year), operating profit of US$23.9M (+32.7% year on year) and net income of US$19.2M (from a loss a year earlier).
Earnings · Aug 11 - Operating results (preliminary) (fair disclosure)
JW Pharmaceutical filed provisional (unaudited) separate results for Q1 2026: revenue of US$133M (+8.1% year on year), operating profit of US$21.2M (+40.4% year on year) and net income of US$19.1M (+62.3% year on year).
Earnings · May 12 - [Amended] Cash/in-kind dividend decision
JW Pharmaceutical updated its declared cash dividend of US$0.44 per share, equal to about 2.1% of the recent share price.
Dividend · Mar 11 · 3 versions - Change of less than 30% in revenue or profit/loss structure (voluntary)Earnings · Feb 2